Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACIU 
AC Immune Ltd (ACIU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: ACIU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.78
1 Year Target Price $9.78
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.75% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 341.03M USD | Price to earnings Ratio - | 1Y Target Price 9.78 |
Price to earnings Ratio - | 1Y Target Price 9.78 | ||
Volume (30-day avg) 4 | Beta 1.59 | 52 Weeks Range 1.43 - 4.00 | Updated Date 11/12/2025 |
52 Weeks Range 1.43 - 4.00 | Updated Date 11/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.1898 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) -1671.89% |
Management Effectiveness
Return on Assets (TTM) -21.97% | Return on Equity (TTM) -74.63% |
Valuation
Trailing PE - | Forward PE 11.24 | Enterprise Value 208408822 | Price to Sales(TTM) 78 |
Enterprise Value 208408822 | Price to Sales(TTM) 78 | ||
Enterprise Value to Revenue 38.48 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 100600000 | Shares Floating 40064895 |
Shares Outstanding 100600000 | Shares Floating 40064895 | ||
Percent Insiders 38.01 | Percent Institutions 24.91 |
Upturn AI SWOT
AC Immune Ltd
Company Overview
History and Background
AC Immune SA is a clinical-stage biopharmaceutical company dedicated to discovering, designing and developing therapeutic and diagnostic products for the prevention and treatment of diseases caused by misfolded proteins. Founded in 2003 in Lausanne, Switzerland, it focuses on neurodegenerative diseases like Alzheimer's and Parkinson's.
Core Business Areas
- Neurodegenerative Disease Therapies: Development of therapies targeting misfolded proteins implicated in Alzheimer's, Parkinson's, and other neurodegenerative diseases. This includes antibody therapeutics and small molecules.
- Diagnostics: Developing diagnostic tools to detect misfolded proteins early in the disease progression, primarily focused on Alzheimer's disease.
Leadership and Structure
The company is led by a CEO and a management team with expertise in drug development and neurology. It operates with a structure that supports research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- Crenezumab (partnered with Roche): An anti-Abeta antibody being investigated for the treatment of early Alzheimer's disease. It is currently in Phase III trials. Competitors include Donanemab (LLY), Lecanemab (Biogen/Eisai).
- ACI-24.060 (Anti-Abeta Active Immunotherapy): Vaccine candidate designed to elicit antibodies against Abeta. Phase 2 clinical trials in Alzheimer's Disease ongoing. Competitors include Axon Neuroscience AADvac1.
- ACI-7104 (Anti-alpha-synuclein antibody): Investigational immunotherapy targeting alpha-synuclein for the treatment of Parkinson's disease and Multiple System Atrophy (MSA). In clinical development, partnered with Lilly (LLY). Competitors include Prasinezumab (Roche).
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing due to aging populations. Alzheimer's and Parkinson's are significant areas of unmet need. The industry is characterized by high risk and long development timelines.
Positioning
AC Immune is positioned as a leader in targeting misfolded proteins for neurodegenerative diseases. Its strengths include a diverse pipeline and partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The global market for Alzheimer's and Parkinson's disease therapies is estimated to be in the tens of billions of dollars annually. AC Immune is targeting a significant portion of this TAM through its innovative approaches.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong partnerships with Roche and Lilly
- Experienced management team
- Diverse pipeline of therapeutic candidates
Weaknesses
- High reliance on clinical trial success
- Limited revenue stream
- Competition from larger pharmaceutical companies
- Cash burn rate
Opportunities
- Positive clinical trial results
- Expansion of partnerships
- Approval of a lead candidate
- Advancement of diagnostic technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- RO.SW
Competitive Landscape
AC Immune competes with large pharmaceutical companies that have greater resources and established market presence. AC Immune's advantage lies in its focus on misfolded proteins and innovative technologies. However, it is behind other competitors in products reaching market.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on pipeline progression and partnerships.
Future Projections: Projections depend on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Advancing pipeline assets into later-stage clinical trials, securing partnerships with major pharmaceutical companies
Summary
AC Immune is a promising clinical-stage biopharmaceutical company focused on neurodegenerative diseases. Its innovative technology and partnerships with Roche and Lilly are strengths, but it faces risks associated with clinical trials and competition. Future success hinges on positive trial results and regulatory approvals. The company has a large addressable market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- AC Immune Ltd. website
- Company SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market share data is an estimate and may not be precise. Investment decisions should be made with careful consideration and professional consultation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AC Immune Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-09-23 | Co-Founder, CEO & Director Dr. Andrea Pfeifer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 133 | Website https://www.acimmune.com |
Full time employees 133 | Website https://www.acimmune.com | ||
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.